All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Irene Biasoli, MD, is an Associate Professor of Hematology in the Internal Medicine Department at the Federal University of Rio de Janeiro, Rio de Janeiro, BR.
She graduated in medicine in 1993 and obtained her specialization in hematology in 1997 from Federal University of Rio de Janeiro. She obtained her MSc in 1999 and PhD in 2004 at the same institution, where she has continued her clinical and research activity. In 2007, she was a postdoctoral researcher in Hôpital St Louis, Paris, FR.
Currently, she coordinates the Brazilian Hodgkin Lymphoma Registry. She is author/co-author of over 35 peer-reviewed papers. Her clinical research interests are focused on lymphoproliferative disorders.